XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.

XM bietet keine Dienstleistungen für Personen mit Wohnsitz in den Vereinigten Staaten von Amerika an.
S
S

Sanofi

Nachrichten

Reuters - vor 2 Stunden

Soros Fund Management LLC Cuts Share Stake In Amazon, Raises In Astrazeneca Plc, American International Group

BRIEF-Soros Fund Management LLC Cuts Share Stake In Amazon, Raises In Astrazeneca Plc, American International Group Aug 14 (Reuters) - Soros Fund Management LLC SOROS FUND MANAGEMENT LLC CUTS SHARE STAKE IN AMAZON COM INC BY 26.5% TO 290,854 SHARES - SEC FILING SOROS FUND MANAGEMENT LLC RAISES SHARE STAKE IN ASTRAZENECA PLC BY 512.9% TO 2.5 MILLION
A
A
M
S
Reuters - vor 3 Stunden

FDA approves Incyte's treatment for chronic graft-versus-host disease

UPDATE 2-FDA approves Incyte's treatment for chronic graft-versus-host disease Rewrites throughout, adds analyst comment in paragraph 9 By Christy Santhosh and Sruthi Narasimha Chari Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Incyte's INCY.O treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.
I
S
Reuters - vor 3 Tagen

MeiraGTx Announces Pricing Of Offering Of Ordinary Shares Led By Sanofi

BRIEF-MeiraGTx Announces Pricing Of Offering Of Ordinary Shares Led By Sanofi Aug 12 (Reuters) - MeiraGTx Holdings PLC MGTX.O : MEIRAGTX ANNOUNCES PRICING OF OFFERING OF ORDINARY SHARES LED BY SANOFI MEIRAGTX HOLDINGS: GROSS PROCEEDS FROM OFFERING EXPECTED TO BE $50 MILLION MEIRAGTX HOLDINGS: PRICING OF UNDERWRITTEN OFFERING OF 12.5 MILLION OF ORDI
S
Reuters - vor 6 Tagen

IDT Australia rises after contract win

BUZZ-IDT Australia rises after contract win ** Shares of IDT Australia IDT.AX rise as much as 8.7% to A$0.125 ** Shares on track for their best day since July 12, if gains hold ** The pharma manufacturer secures contract with Sanofi Australia for pre-clinical formulation, development and manufacture of Sanofi's messenger RNA technology for its tran
S
Reuters - vor 6 Tagen

German panel endorses GSK, Pfizer RSV vaccines for elderly

German panel endorses GSK, Pfizer RSV vaccines for elderly FRANKFURT, Aug 8 (Reuters) - Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV. The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L , should be administered ideally in September or October before the cold
A
G
P
S
Reuters - vor 1 Woche

Novavax cuts 2024 revenue forecast, shrinks European presence

UPDATE 3-Novavax cuts 2024 revenue forecast, shrinks European presence Adds executive comments in paragraphs 3 and 5 By Leroy Leo Aug 8 (Reuters) - Novavax NVAX.O on Thursday trimmed its annual revenue forecast again and said it would pare back its presence in Europe through the rest of the year, ahead of handing over the rights to sell its COVID-19 vaccine to partner Sanofi SASY.PA in 2025. The company's vaccine had failed to make a significant dent in the market share of early COVID-vaccine en
P
S
Reuters - vor 1 Woche

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Biotech firm Recursion to buy smaller peer Exscientia for $688 million By Anirban Sen NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals RXRX.O , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia EXAI.O for $688 million in an all-stock deal, according to a statement seen by Reuters.
B
N
R
S
Reuters - vor 1 Woche

Third trial over Zantac cancer claims ends with hung jury

UPDATE 1-Third trial over Zantac cancer claims ends with hung jury Adds response from plaintiff's attorney in paragraphs 2-3 By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
G
P
S
Reuters - vor 1 Woche

Third trial over Zantac cancer claims ends with hung jury

Third trial over Zantac cancer claims ends with hung jury By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer, according to the plaintiff's lawyer.
G
P
S
Reuters - vor 1 Woche

GSK wins latest trial over Zantac cancer claims

GSK wins latest trial over Zantac cancer claims By Brendan Pierson Aug 5 (Reuters) - GSK GSK.L won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spokesperson said. Carrie Joiner had alleged in her lawsuit in state court in Chicago that she developed colorectal cancer from a carcinogenic contaminant called NDMA found in the once-blockuster drug.
G
P
S
Reuters - vor 2 Wochen

European shares tumble as global equity rout amplifies

UPDATE 2-European shares tumble as global equity rout amplifies For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 drops 2.7% France's AXA gains after deal talks with BNP Paribas Tech index slides 6.1%, banks index off 4.3% STOXX fear gauge touches highest level since March 2023 Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan Aug 2 (Reuters) - Europe' s STOXX 600 fell close to 3% on Friday as global equity markets ran i
A
A
B
N
S
E
F
U
G
Reuters - vor 2 Wochen

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Regeneron beats quarterly results on strong demand for eczema, eye treatments Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
B
R
R
S
Reuters - vor 2 Wochen

Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt

Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt BERLIN, Aug 1 (Reuters) - French drugmaker Sanofi SASY.PA will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where it makes insulin brand Lantus, the company said on Thursday. The investment will pave the way for the construction of a 36,000-square-metre facility that will replace Sanofi's current insulin production plant in Frankfurt's Hoechst district by 2029, the
S
Reuters - vor 2 Wochen

Sanofi Plans To Build Insulin Production Facility In Frankfurt

BRIEF-Sanofi Plans To Build Insulin Production Facility In Frankfurt Aug 1 (Reuters) - Sanofi SA SASY.PA : SANOFI: PLANS TO BUILD INSULIN PRODUCTION FACILITY AT BIOCAMPUS IN FRANKFURT, INVESTMENT VALUE THROUGH 2029 OF 1.3 BILLION EUR Source text for Eikon: [ID:] Further company coverage: SASY.PA
S
Reuters - vor 2 Wochen

Novavax falls after J.P. Morgan downgrades to 'underweight'

BUZZ-Novavax falls after J.P. Morgan downgrades to 'underweight' Updates ** Shares of vaccine maker Novavax NVAX.O fell as much as 34.2% to hit a two-month low of $11.63 ** Stock was last down 26% and was on track for its biggest daily drop in five months ** J.P. Morgan downgrades stock to "underweight" from "neutral", sets PT of $8 ** Levels after
S
Reuters - vor 2 Wochen

Patients push back against Novo Nordisk move to scrap an insulin product

UPDATE 1-FOCUS-Patients push back against Novo Nordisk move to scrap an insulin product Patients want to keep Levemir insulin on market in US Novo Nordisk: other long-acting insulins are safe alternatives Company under scrutiny in Congress over high price of Wegovy Adds detail from Novo response in paragraph 9 By Maggie Fick and Ahmed Aboulenein LONDON/WASHINGTON, July 30 (Reuters) - Novo Nordisk's NOVOb.CO decision to stop selling its long-acting insulin Levemir in the United States has left so
S
Reuters - vor 2 Wochen

Novavax falls after J.P. Morgan downgrades to 'underweight'

BUZZ-Novavax falls after J.P. Morgan downgrades to 'underweight' Updates ** Shares of vaccine maker Novavax NVAX.O fall 8.16% to $15.08 premarket ** J.P. Morgan downgrades to "underweight" from "neutral", sets PT of $8 ** Says levels after the Sanofi SASY.PA deal is unsupported by moderate forecast for COVID-influenza combo and COVID vaccines ** Up
S
Reuters - vor 2 Wochen

Novavax falls after J.P. Morgan downgrades to 'underweight'

BUZZ-Novavax falls after J.P. Morgan downgrades to 'underweight' ** Shares of vaccine maker Novavax NVAX.O fall 11.02% to $14.61 premarket ** J.P. Morgan downgrades to "underweight" from "neutral" ** Says levels after the Sanofi SASY.PA deal is unsupported by moderate forecast for COVID-influenza combo and COVID vaccines ** Up to last close, NVAX s
S
Reuters - vor 2 Wochen

Patients push back against Novo Nordisk move to scrap an insulin product

CORRECTED-FOCUS-Patients push back against Novo Nordisk move to scrap an insulin product Corrects the market value of Novo Nordisk to include unlisted shares, in paragraph 8 Patients want to keep Levemir insulin on market in U.S. Novo Nordisk: other long-acting insulins are safe alternatives Company under scrutiny in Congress over high price of Wegovy By Maggie Fick and Ahmed Aboulenein LONDON/WASHINGTON, July 30 (Reuters) - Novo Nordisk's NOVOb.CO decision to stop selling its long-acting insuli
S
Reuters - vor 2 Wochen

Euronext, Pearson, Saint-Gobain

EUROPE RESEARCH ROUNDUP- Euronext, Pearson, Saint-Gobain July 30 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Euronext, Pearson and Saint-Gobain on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : HSBC cuts target price to EUR 1600 from EUR 1900 * Deutsche Boerse AG DB1Gn.DE : JP Morgan raises target price to EUR 198 from EUR 194 * Euronext NV ENX.PA : JP Morgan cuts target price to EUR 107 from EUR 108 * Pearson PSON.L : JP Morgan cut
A
C
C
D
D
E
E
H
H
L
L
P
P
P
R
S
S
S
A
D
J
S

Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Risikowarnung: Es bestehen Risiken für Ihr eingesetztes Kapital. Gehebelte Produkte sind nicht für alle Anleger geeignet. Bitte beachten Sie unseren Risikohinweis.